Aurobindo Pharma to expand its US portfolio; eyeing new markets in Europe
The Dollar Business Bureau A leading Indian pharmaceuticals company Aurobindo Pharma has said that it would widen its product portfolio in the American market while planning to enter new markets in the Europe, a part of the company’s growth strategy in the coming 3-4 years. In the US market, Aurobindo Pharma plans to widen its portfolio through faster growth in OTC, injectable and higher complexity products, the company said in a presentation to investors. However, in European market, the company plans to enhance its presence in new geographies like Czech Republic and Poland, in addition to strengthening its position in the existing markets of Germany, France, Spain, Netherlands and the UK. Aurobindo Pharma is the 6th largest generic company by volume in the US, ...
Pharma issues left unaddressed in the Union Budget: Expert
Sai Nikesh | The Dollar Business In view of the Union Budget and India witnessing significant tax reforms in bringing in a single comprehensive tax on goods and services, The Pharma Export Promotion Council on Monday, organised a post-budget interactive session in association with the Ernst & Young (E&Y) as the knowledge partner in Hyderabad. The meeting discussed critical issues that would help the Pharmaceutical Industry plan for the changes that are likely to evolve in the aftermath of Budget 2015-16 as also bring together the industry's point of view on the implications stemming from the budget. Speaking to The Dollar Business P V Appaji, Director General, Pharmexcil, said, “There is a need for investments aimed at quality improvement ...
